Delaware | 000-50976 | 01-0666114 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification Number) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Huron Consulting Group Inc. | |||
(Registrant) | |||
Date: | November 1, 2016 | /s/ C. Mark Hussey | |
C. Mark Hussey | |||
Executive Vice President, Chief Operating Officer and Chief Financial Officer |
Exhibit Number | Description | |
99.1 | Press release, dated November 1, 2016 |
NEWS | MEDIA CONTACT | |
Sarah McHugh | ||
FOR IMMEDIATE RELEASE | 312-880-2624 | |
smchugh@huronconsultinggroup.com | ||
INVESTOR CONTACT | ||
C. Mark Hussey | ||
or | ||
John D. Kelly | ||
312-583-8722 | ||
investor@huronconsultinggroup.com |
• | Revenues increased 4.5% to $183.4 million in Q3 2016 from $175.5 million in Q3 2015, and increased 6.7% to $548.1 million for the first nine months of 2016 from $513.9 million for the same period in 2015. |
• | Net income from continuing operations was $12.3 million in Q3 2016 compared to $14.3 million in Q3 2015, and increased 20.1% to $35.3 million for the first nine months of 2016 from $29.4 million for the same period in 2015. |
• | Adjusted EBITDA(6), a non-GAAP measure, was $36.9 million in Q3 2016 compared to $41.7 million in Q3 2015, and increased 5.6% to $104.8 million for the first nine months of 2016 from $99.3 million for the same period in 2015. |
• | Diluted earnings per share from continuing operations was $0.57 in Q3 2016 compared to $0.63 in Q3 2015, and increased 26.9% to $1.65 for the first nine months of 2016 compared to $1.30 for the first nine months of 2015. |
• | Adjusted diluted earnings per share from continuing operations(6), a non-GAAP measure, increased to $0.92 in Q3 2016 from $0.90 in Q3 2015, and increased 28.3% to $2.63 for the first nine months of 2016 from $2.05 for the first nine months of 2015. |
• | Company updates full year 2016 guidance, including revenue guidance to a range of $730.0 million to $740.0 million. |
Three Months Ended September 30, | |||||||
2016 | 2015 | ||||||
Amortization of intangible assets | $ | 8,771 | $ | 7,913 | |||
Restructuring charges | $ | 1,049 | $ | 320 | |||
Other losses | $ | 494 | $ | — | |||
Non-cash interest on convertible notes | $ | 1,883 | $ | 1,795 | |||
Tax effect | $ | (4,794 | ) | $ | (3,951 | ) |
Nine Months Ended September 30, | |||||||
2016 | 2015 | ||||||
Amortization of intangible assets | $ | 24,369 | $ | 20,685 | |||
Restructuring charges | $ | 4,129 | $ | 1,577 | |||
Other losses, net | $ | 494 | $ | 524 | |||
Non-cash interest on convertible notes | $ | 5,582 | $ | 5,324 | |||
Tax effect | $ | (13,588 | ) | $ | (11,075 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Revenues and reimbursable expenses: | |||||||||||||||
Revenues | $ | 183,400 | $ | 175,465 | $ | 548,148 | $ | 513,910 | |||||||
Reimbursable expenses | 19,093 | 16,091 | 54,636 | 53,266 | |||||||||||
Total revenues and reimbursable expenses | 202,493 | 191,556 | 602,784 | 567,176 | |||||||||||
Direct costs and reimbursable expenses (exclusive of depreciation and amortization shown in operating expenses): | |||||||||||||||
Direct costs | 108,354 | 94,821 | 323,310 | 297,448 | |||||||||||
Amortization of intangible assets and software development costs | 4,052 | 4,738 | 11,278 | 12,102 | |||||||||||
Reimbursable expenses | 18,956 | 15,837 | 54,747 | 53,194 | |||||||||||
Total direct costs and reimbursable expenses | 131,362 | 115,396 | 389,335 | 362,744 | |||||||||||
Operating expenses and other losses, net: | |||||||||||||||
Selling, general and administrative expenses | 38,256 | 39,246 | 119,937 | 117,256 | |||||||||||
Restructuring charges | 1,049 | 320 | 4,129 | 1,577 | |||||||||||
Other losses, net | 494 | — | 494 | 524 | |||||||||||
Depreciation and amortization | 8,092 | 6,538 | 23,064 | 18,286 | |||||||||||
Total operating expenses and other losses, net | 47,891 | 46,104 | 147,624 | 137,643 | |||||||||||
Operating income | 23,240 | 30,056 | 65,825 | 66,789 | |||||||||||
Other income (expense), net: | |||||||||||||||
Interest expense, net of interest income | (4,176 | ) | (4,638 | ) | (12,270 | ) | (13,794 | ) | |||||||
Other income (expense), net | 489 | (1,400 | ) | 1,236 | (1,982 | ) | |||||||||
Total other expense, net | (3,687 | ) | (6,038 | ) | (11,034 | ) | (15,776 | ) | |||||||
Income from continuing operations before income tax expense | 19,553 | 24,018 | 54,791 | 51,013 | |||||||||||
Income tax expense | 7,265 | 9,741 | 19,498 | 21,620 | |||||||||||
Net income from continuing operations | 12,288 | 14,277 | 35,293 | 29,393 | |||||||||||
Income (loss) from discontinued operations, net of tax | 4 | 5,097 | (1,830 | ) | 10,316 | ||||||||||
Net income | $ | 12,292 | $ | 19,374 | $ | 33,463 | $ | 39,709 | |||||||
Net earnings per basic share: | |||||||||||||||
Net income from continuing operations | $ | 0.58 | $ | 0.65 | $ | 1.67 | $ | 1.33 | |||||||
Income (loss) from discontinued operations, net of tax | — | 0.23 | (0.08 | ) | 0.46 | ||||||||||
Net income | $ | 0.58 | $ | 0.88 | $ | 1.59 | $ | 1.79 | |||||||
Net earnings per diluted share: | |||||||||||||||
Net income from continuing operations | $ | 0.57 | $ | 0.63 | $ | 1.65 | $ | 1.30 | |||||||
Income (loss) from discontinued operations, net of tax | — | 0.23 | (0.09 | ) | 0.46 | ||||||||||
Net income | $ | 0.57 | $ | 0.86 | $ | 1.56 | $ | 1.76 | |||||||
Weighted average shares used in calculating earnings per share: | |||||||||||||||
Basic | 21,076 | 22,107 | 21,084 | 22,151 | |||||||||||
Diluted | 21,445 | 22,592 | 21,427 | 22,616 | |||||||||||
Comprehensive income: | |||||||||||||||
Net income | $ | 12,292 | $ | 19,374 | $ | 33,463 | $ | 39,709 | |||||||
Foreign currency translation adjustments, net of tax | 50 | (615 | ) | 52 | (201 | ) | |||||||||
Unrealized gain (loss) on investment, net of tax | (2,038 | ) | — | (1,163 | ) | 4,135 | |||||||||
Unrealized gain (loss) on cash flow hedging instruments, net of tax | 121 | (91 | ) | (27 | ) | (252 | ) | ||||||||
Other comprehensive income (loss) | (1,867 | ) | (706 | ) | (1,138 | ) | 3,682 | ||||||||
Comprehensive income | $ | 10,425 | $ | 18,668 | $ | 32,325 | $ | 43,391 |
September 30, 2016 | December 31, 2015 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 9,103 | $ | 58,437 | |||
Receivables from clients, net | 88,387 | 85,297 | |||||
Unbilled services, net | 71,594 | 56,527 | |||||
Income tax receivable | 2,711 | 406 | |||||
Prepaid expenses and other current assets | 12,772 | 27,720 | |||||
Total current assets | 184,567 | 228,387 | |||||
Property and equipment, net | 30,099 | 28,888 | |||||
Long-term investment | 32,932 | 34,831 | |||||
Other non-current assets | 23,448 | 21,045 | |||||
Intangible assets, net | 90,090 | 94,992 | |||||
Goodwill | 799,958 | 751,400 | |||||
Total assets | $ | 1,161,094 | $ | 1,159,543 | |||
Liabilities and stockholders’ equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 6,696 | $ | 7,220 | |||
Accrued expenses | 23,013 | 24,276 | |||||
Accrued payroll and related benefits | 62,341 | 80,839 | |||||
Deferred revenues | 22,158 | 19,086 | |||||
Total current liabilities | 114,208 | 131,421 | |||||
Non-current liabilities: | |||||||
Deferred compensation and other liabilities | 33,511 | 23,768 | |||||
Long-term debt | 325,858 | 307,376 | |||||
Deferred lease incentives | 9,838 | 9,965 | |||||
Deferred income taxes, net | 38,659 | 34,688 | |||||
Total non-current liabilities | 407,866 | 375,797 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity | |||||||
Common stock; $0.01 par value; 500,000,000 shares authorized; 24,120,541 and 24,775,823 shares issued at September 30, 2016 and December 31, 2015, respectively | 235 | 241 | |||||
Treasury stock, at cost, 2,395,473 and 2,249,630 shares at September 30, 2016 and December 31, 2015, respectively | (112,329 | ) | (103,734 | ) | |||
Additional paid-in capital | 401,338 | 438,367 | |||||
Retained earnings | 347,329 | 313,866 | |||||
Accumulated other comprehensive income | 2,447 | 3,585 | |||||
Total stockholders’ equity | 639,020 | 652,325 | |||||
Total liabilities and stockholders’ equity | $ | 1,161,094 | $ | 1,159,543 |
Nine Months Ended September 30, | |||||||
2016 | 2015 | ||||||
Cash flows from operating activities: | |||||||
Net income | $ | 33,463 | $ | 39,709 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation and amortization | 34,344 | 38,220 | |||||
Share-based compensation | 13,145 | 15,288 | |||||
Amortization of debt discount and issuance costs | 7,171 | 6,985 | |||||
Allowances for doubtful accounts and unbilled services | 7,107 | (1,605 | ) | ||||
Deferred income taxes | 4,045 | 13,407 | |||||
Changes in operating assets and liabilities, net of acquisitions: | |||||||
(Increase) decrease in receivables from clients | 9,442 | (14,725 | ) | ||||
(Increase) decrease in unbilled services | (21,492 | ) | 15,179 | ||||
(Increase) decrease in current income tax receivable / payable, net | (3,039 | ) | 3,704 | ||||
(Increase) decrease in other assets | 12,669 | (5,381 | ) | ||||
Increase (decrease) in accounts payable and accrued liabilities | (2,366 | ) | 8,459 | ||||
Increase (decrease) in accrued payroll and related benefits | (17,707 | ) | (43,510 | ) | |||
Increase (decrease) in deferred revenues | 2,028 | 7,507 | |||||
Net cash provided by operating activities | 78,810 | 83,237 | |||||
Cash flows from investing activities: | |||||||
Purchases of property and equipment, net | (9,372 | ) | (15,040 | ) | |||
Investment in life insurance policies | (1,890 | ) | (4,823 | ) | |||
Purchases of businesses, net of cash acquired | (69,133 | ) | (332,766 | ) | |||
Purchase of convertible debt investment | — | (15,138 | ) | ||||
Capitalization of internally developed software costs | (838 | ) | (735 | ) | |||
Net cash used in investing activities | (81,233 | ) | (368,502 | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from exercise of stock options | 123 | — | |||||
Shares redeemed for employee tax withholdings | (4,837 | ) | (5,194 | ) | |||
Tax benefit from share-based compensation | 935 | 3,117 | |||||
Share repurchases | (55,265 | ) | (13,498 | ) | |||
Proceeds from borrowings under credit facility | 168,000 | 272,000 | |||||
Repayments on credit facility | (156,000 | ) | (214,500 | ) | |||
Payments for capital lease obligations | — | (48 | ) | ||||
Net cash provided by (used in) financing activities | (47,044 | ) | 41,877 | ||||
Effect of exchange rate changes on cash | 133 | (22 | ) | ||||
Net decrease in cash and cash equivalents | (49,334 | ) | (243,410 | ) | |||
Cash and cash equivalents at beginning of the period | 58,437 | 256,872 | |||||
Cash and cash equivalents at end of the period | $ | 9,103 | $ | 13,462 |
Three Months Ended September 30, | Percent Increase (Decrease) | ||||||||||
Segment and Consolidated Operating Results (in thousands): | 2016 | 2015 | |||||||||
Huron Healthcare: | |||||||||||
Revenues | $ | 103,425 | $ | 112,114 | (7.8 | )% | |||||
Operating income | $ | 38,824 | $ | 47,609 | (18.5 | )% | |||||
Segment operating income as a percentage of segment revenues | 37.5 | % | 42.5 | % | |||||||
Huron Education and Life Sciences: | |||||||||||
Revenues | $ | 45,696 | $ | 42,056 | 8.7 | % | |||||
Operating income | $ | 12,124 | $ | 10,473 | 15.8 | % | |||||
Segment operating income as a percentage of segment revenues | 26.5 | % | 24.9 | % | |||||||
Huron Business Advisory: | |||||||||||
Revenues | $ | 34,279 | $ | 21,249 | 61.3 | % | |||||
Operating income | $ | 7,380 | $ | 5,231 | 41.1 | % | |||||
Segment operating income as a percentage of segment revenues | 21.5 | % | 24.6 | % | |||||||
All Other: | |||||||||||
Revenues | $ | — | $ | 46 | (100.0 | )% | |||||
Operating loss | $ | — | $ | (132 | ) | (100.0 | )% | ||||
Segment operating loss as a percentage of segment revenues | N/M | N/M | |||||||||
Total Company: | |||||||||||
Revenues | $ | 183,400 | $ | 175,465 | 4.5 | % | |||||
Reimbursable expenses | 19,093 | 16,091 | 18.7 | % | |||||||
Total revenues and reimbursable expenses | $ | 202,493 | $ | 191,556 | 5.7 | % | |||||
Statements of Earnings reconciliation: | |||||||||||
Segment operating income | $ | 58,328 | $ | 63,181 | (7.7 | )% | |||||
Items not allocated at the segment level: | |||||||||||
Other operating expenses and losses, net | 26,996 | 26,587 | 1.5 | % | |||||||
Depreciation and amortization expense | 8,092 | 6,538 | 23.8 | % | |||||||
Total operating income | 23,240 | 30,056 | (22.7 | )% | |||||||
Other expense, net | 3,687 | 6,038 | (38.9 | )% | |||||||
Income from continuing operations before income tax expense | $ | 19,553 | $ | 24,018 | (18.6 | )% | |||||
Other Operating Data (excluding All Other): | |||||||||||
Number of full-time billable consultants (at period end) (1): | |||||||||||
Huron Healthcare | 1,010 | 1,084 | (6.8 | )% | |||||||
Huron Education and Life Sciences | 539 | 458 | 17.7 | % | |||||||
Huron Business Advisory | 472 | 279 | 69.2 | % | |||||||
Total | 2,021 | 1,821 | 11.0 | % | |||||||
Average number of full-time billable consultants (for the period) (1): | |||||||||||
Huron Healthcare | 984 | 1,078 | |||||||||
Huron Education and Life Sciences | 523 | 444 | |||||||||
Huron Business Advisory | 454 | 261 | |||||||||
Total | 1,961 | 1,783 |
Three Months Ended September 30, | ||||||||
Other Operating Data (continued): | 2016 | 2015 | ||||||
Full-time billable consultant utilization rate (2): | ||||||||
Huron Healthcare | 77.0 | % | 81.1 | % | ||||
Huron Education and Life Sciences | 67.6 | % | 75.2 | % | ||||
Huron Business Advisory | 74.8 | % | 79.4 | % | ||||
Total | 73.9 | % | 79.4 | % | ||||
Full-time billable consultant average billing rate per hour (3): | ||||||||
Huron Healthcare | $ | 203 | $ | 204 | ||||
Huron Education and Life Sciences | $ | 231 | $ | 227 | ||||
Huron Business Advisory | $ | 190 | $ | 196 | ||||
Total | $ | 207 | $ | 209 | ||||
Revenue per full-time billable consultant (in thousands): | ||||||||
Huron Healthcare | $ | 73 | $ | 77 | ||||
Huron Education and Life Sciences | $ | 75 | $ | 80 | ||||
Huron Business Advisory | $ | 69 | $ | 77 | ||||
Total | $ | 72 | $ | 78 | ||||
Average number of full-time equivalents (for the period) (5): | ||||||||
Huron Healthcare | 204 | 196 | ||||||
Huron Education and Life Sciences | 42 | 49 | ||||||
Huron Business Advisory | 23 | 10 | ||||||
Total | 269 | 255 | ||||||
Revenue per full-time equivalent (in thousands): | ||||||||
Huron Healthcare | $ | 156 | $ | 148 | ||||
Huron Education and Life Sciences | $ | 156 | $ | 133 | ||||
Huron Business Advisory | $ | 126 | $ | 112 | ||||
Total | $ | 154 | $ | 144 |
Nine Months Ended September 30, | Percent Increase (Decrease) | ||||||||||
Segment and Consolidated Operating Results (in thousands): | 2016 | 2015 | |||||||||
Huron Healthcare: | |||||||||||
Revenues | $ | 323,531 | $ | 328,624 | (1.5 | )% | |||||
Operating income | $ | 119,229 | $ | 122,120 | (2.4 | )% | |||||
Segment operating income as a percentage of segment revenues | 36.9 | % | 37.2 | % | |||||||
Huron Education and Life Sciences: | |||||||||||
Revenues | $ | 134,050 | $ | 124,892 | 7.3 | % | |||||
Operating income | $ | 35,407 | $ | 35,427 | (0.1 | )% | |||||
Segment operating income as a percentage of segment revenues | 26.4 | % | 28.4 | % | |||||||
Huron Business Advisory: | |||||||||||
Revenues | $ | 90,567 | $ | 59,173 | 53.1 | % | |||||
Operating income | $ | 19,342 | $ | 13,514 | 43.1 | % | |||||
Segment operating income as a percentage of segment revenues | 21.4 | % | 22.8 | % | |||||||
All Other: | |||||||||||
Revenues | $ | — | $ | 1,221 | (100.0 | )% | |||||
Operating loss | $ | — | $ | (1,654 | ) | (100.0 | )% | ||||
Segment operating loss as a percentage of segment revenues | N/M | N/M | |||||||||
Total Company: | |||||||||||
Revenues | $ | 548,148 | $ | 513,910 | 6.7 | % | |||||
Reimbursable expenses | 54,636 | 53,266 | 2.6 | % | |||||||
Total revenues and reimbursable expenses | $ | 602,784 | $ | 567,176 | 6.3 | % | |||||
Statements of Earnings reconciliation: | |||||||||||
Segment operating income | $ | 173,978 | $ | 169,407 | 2.7 | % | |||||
Items not allocated at the segment level: | |||||||||||
Other operating expenses and losses, net | 85,089 | 84,332 | 0.9 | % | |||||||
Depreciation and amortization expense | 23,064 | 18,286 | 26.1 | % | |||||||
Total operating income | 65,825 | 66,789 | (1.4 | )% | |||||||
Other expense, net | 11,034 | 15,776 | (30.1 | )% | |||||||
Income from continuing operations before income tax expense | $ | 54,791 | $ | 51,013 | 7.4 | % | |||||
Other Operating Data (excluding All Other): | |||||||||||
Number of full-time billable consultants (at period end) (1): | |||||||||||
Huron Healthcare | 1,010 | 1,084 | (6.8 | )% | |||||||
Huron Education and Life Sciences | 539 | 458 | 17.7 | % | |||||||
Huron Business Advisory | 472 | 279 | 69.2 | % | |||||||
Total | 2,021 | 1,821 | 11.0 | % | |||||||
Average number of full-time billable consultants (for the period) (1): | |||||||||||
Huron Healthcare | 1,005 | 1,092 | |||||||||
Huron Education and Life Sciences | 503 | 431 | |||||||||
Huron Business Advisory | 387 | 224 | |||||||||
Total | 1,895 | 1,747 |
Nine Months Ended September 30, | ||||||||
Other Operating Data (continued): | 2016 | 2015 | ||||||
Full-time billable consultant utilization rate (2): | ||||||||
Huron Healthcare | 78.6 | % | 76.4 | % | ||||
Huron Education and Life Sciences | 70.1 | % | 75.9 | % | ||||
Huron Business Advisory | 74.0 | % | 75.2 | % | ||||
Total | 75.3 | % | 76.1 | % | ||||
Full-time billable consultant average billing rate per hour (3): | ||||||||
Huron Healthcare | $ | 209 | $ | 215 | ||||
Huron Education and Life Sciences | $ | 229 | $ | 230 | ||||
Huron Business Advisory (4) | $ | 201 | $ | 234 | ||||
Total | $ | 212 | $ | 221 | ||||
Revenue per full-time billable consultant (in thousands): | ||||||||
Huron Healthcare | $ | 231 | $ | 230 | ||||
Huron Education and Life Sciences | $ | 233 | $ | 248 | ||||
Huron Business Advisory | $ | 220 | $ | 254 | ||||
Total | $ | 229 | $ | 238 | ||||
Average number of full-time equivalents (for the period) (5): | ||||||||
Huron Healthcare | 201 | 171 | ||||||
Huron Education and Life Sciences | 40 | 40 | ||||||
Huron Business Advisory | 16 | 8 | ||||||
Total | 257 | 219 | ||||||
Revenue per full-time equivalent (in thousands): | ||||||||
Huron Healthcare | $ | 456 | $ | 449 | ||||
Huron Education and Life Sciences | $ | 428 | $ | 455 | ||||
Huron Business Advisory | $ | 339 | $ | 301 | ||||
Total | $ | 444 | $ | 445 |
(1) | Consists of our full-time professionals who provide consulting services and generate revenues based on the number of hours worked. |
(2) | Utilization rate for our full-time billable consultants is calculated by dividing the number of hours all of our full-time billable consultants worked on client assignments during a period by the total available working hours for all of these consultants during the same period, assuming a forty-hour work week, less paid holidays and vacation days. |
(3) | Average billing rate per hour for our full-time billable consultants is calculated by dividing revenues for a period by the number of hours worked on client assignments during the same period. |
(4) | The Huron Business Advisory segment includes our India EPM&A practice, formerly known as Rittman Mead Consulting Private Limited, a business that we acquired in July 2015. Absent the impact of our India EPM&A practice, the average billing rate per hour for Huron Business Advisory for the nine months ended September 30, 2016 and 2015 would have been $234 and $255, respectively. |
(5) | Consists of cultural transformation consultants within our Studer Group solution, which include coaches and their support staff, consultants who work variable schedules as needed by our clients, and full-time employees who provide software support and maintenance services to our clients. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Revenues | $ | 183,400 | $ | 175,465 | $ | 548,148 | $ | 513,910 | |||||||
Net income from continuing operations | $ | 12,288 | $ | 14,277 | $ | 35,293 | $ | 29,393 | |||||||
Add back: | |||||||||||||||
Income tax expense | 7,265 | 9,741 | 19,498 | 21,620 | |||||||||||
Interest and other expenses | 3,687 | 6,038 | 11,034 | 15,776 | |||||||||||
Depreciation and amortization | 12,144 | 11,276 | 34,342 | 30,388 | |||||||||||
Earnings before interest, taxes, depreciation and amortization (EBITDA) (6) | 35,384 | 41,332 | 100,167 | 97,177 | |||||||||||
Add back: | |||||||||||||||
Restructuring charges | 1,049 | 320 | 4,129 | 1,577 | |||||||||||
Other losses, net | 494 | — | 494 | 524 | |||||||||||
Adjusted EBITDA (6) | $ | 36,927 | $ | 41,652 | $ | 104,790 | $ | 99,278 | |||||||
Adjusted EBITDA as a percentage of revenues (6) | 20.1 | % | 23.7 | % | 19.1 | % | 19.3 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Net income from continuing operations | $ | 12,288 | $ | 14,277 | $ | 35,293 | $ | 29,393 | |||||||
Weighted average shares – diluted | 21,445 | 22,592 | 21,427 | 22,616 | |||||||||||
Diluted earnings per share from continuing operations | $ | 0.57 | $ | 0.63 | $ | 1.65 | $ | 1.30 | |||||||
Add back: | |||||||||||||||
Amortization of intangible assets | 8,771 | 7,913 | 24,369 | 20,685 | |||||||||||
Restructuring charges | 1,049 | 320 | 4,129 | 1,577 | |||||||||||
Other losses, net | 494 | — | 494 | 524 | |||||||||||
Non-cash interest on convertible notes | 1,883 | 1,795 | 5,582 | 5,324 | |||||||||||
Tax effect | (4,794 | ) | (3,951 | ) | (13,588 | ) | (11,075 | ) | |||||||
Total adjustments, net of tax | 7,403 | 6,077 | 20,986 | 17,035 | |||||||||||
Adjusted net income from continuing operations (6) | $ | 19,691 | $ | 20,354 | $ | 56,279 | $ | 46,428 | |||||||
Adjusted diluted earnings per share from continuing operations (6) | $ | 0.92 | $ | 0.90 | $ | 2.63 | $ | 2.05 |
(6) | In evaluating the Company’s financial performance and outlook, management uses earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted EBITDA as a percentage of revenues, adjusted net income from continuing operations, and adjusted diluted earnings per share from continuing operations, which are non-GAAP measures. Our management uses these non-GAAP financial measures to gain an understanding of our comparative operating performance (when comparing such results with previous periods or forecasts). These non-GAAP financial measures are used by management in their financial and operating decision making because management believes they reflect our ongoing business in a manner that allows for meaningful period-to-period comparisons. Management also uses these non-GAAP financial measures when publicly providing our business outlook, for internal management purposes, and as a basis for evaluating potential acquisitions and dispositions. We believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating Huron’s current operating performance and future prospects in the same manner as management does, if they so choose, and in comparing in a consistent manner Huron’s current financial results with Huron’s past financial results. Investors should recognize that these non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance with accounting principles generally accepted in the United States. |
Year Ending | |||||||
December 31, 2016 | |||||||
Guidance Range | |||||||
Low | High | ||||||
Projected revenues - GAAP | $ | 730.0 | $ | 740.0 | |||
Projected net income from continuing operations - GAAP | $ | 43.0 | $ | 45.0 | |||
Add back: | |||||||
Income tax expense | 26.0 | 27.5 | |||||
Interest and other expenses | 16.0 | 16.0 | |||||
Depreciation and amortization | 47.0 | 47.0 | |||||
Projected earnings before interest, taxes, depreciation and amortization (EBITDA) (7) | 132.0 | 135.5 | |||||
Add back: | |||||||
Restructuring charges | 4.5 | 4.5 | |||||
Other losses, net | 0.5 | 0.5 | |||||
Projected adjusted EBITDA (7) | $ | 137.0 | $ | 140.5 | |||
Projected adjusted EBITDA as a percentage of projected revenues (7) | 18.8 | % | 19.0 | % |
Year Ending | |||||||
December 31, 2016 | |||||||
Guidance Range | |||||||
Low | High | ||||||
Projected net income from continuing operations - GAAP | $ | 43.0 | $ | 45.0 | |||
Projected diluted earnings per share from continuing operations - GAAP | $ | 2.00 | $ | 2.10 | |||
Add back: | |||||||
Amortization of intangible assets | 33.0 | 33.0 | |||||
Restructuring charges | 4.5 | 4.5 | |||||
Other losses, net | 0.5 | 0.5 | |||||
Non-cash interest on convertible notes | 7.5 | 7.5 | |||||
Tax effect | (18.5 | ) | (18.5 | ) | |||
Total adjustments, net of tax | 27.0 | 27.0 | |||||
Projected adjusted net income from continuing operations (7) | $ | 70.0 | $ | 72.0 | |||
Projected adjusted diluted earnings per share from continuing operations (7) | $ | 3.25 | $ | 3.35 |
(7) | In evaluating the Company’s outlook, management uses projected EBITDA, projected adjusted EBITDA, projected adjusted EBITDA as a percentage of revenues, projected adjusted net income from continuing operations, and projected adjusted diluted earnings per share from continuing operations, which are non-GAAP measures. Management believes that the use of such measures, as supplements to projected net income from continuing operations and projected diluted earnings per share from continuing operations, and other GAAP measures, are useful indicators for investors. These useful indicators can help readers gain a meaningful understanding of the Company’s core operating results and future prospects without the effect of non-cash or other one-time items. Investors should recognize that these non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance with accounting principles generally accepted in the United States. |